Dr. Hilla Ben-Pazi
Avertto, an Israeli medtech startup, offers the world’s first medical device with an AI- alert that warns a user of an impending stroke, thereby enabling early treatment. It is based on biological mimicry. This is yet another example of how the companies coming out of Israel Startup Nation are leading the world in medical, as well as high-tech, innovations.
Founded in 2019, Avertto offers the first insertable medical device with an AI alert of impending strokes. Stroke is a $1 trillion problem around the world. It is the leading cause of disability. Stroke is treatable if detected in time; however, 85% of the cases remain untreated.
Avertto deals with this problem with its patented, subcutaneous telemonitoring medical device that uses AI and signal analysis to detect changes in the carotid pulse waves, sends “timely alerts” to prevent stroke before neurological damage occurs to healthcare providers, and enables early treatment.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at office@jewishbusinessnews.com.
Thank you.
Just think of this as another form of “light onto nations.”
One woman who can take personal credit for part of this is Dr. Hilla Ben-Pazi. In a world where young girls do not seek careers in the fields of medicine and science – largely due to social and cultural constraints – she is a role model for all young girls and women who wish to be professionals while also raising families.
This is someone who stands as a role model, a heroine, to all women
An expert in pediatric movement disorders, in 2005 she opened Israel’s first clinic in this field at Shaare Zedek Medical Center in Jerusalem.
Dr. Ben-Pazi grew up in an orthodox family – one that observes the many aspects of Jewish law such as keeping Kosher and strict adherence to the keeping of Shabbat. Her father did not want her to be a doctor. Not for religious reasons, not because she is a woman, but because he thought it would be too hard, too difficult to pursue a career in medicine.
Thankfully, for the many people she has helped to date, and the many who will be helped in the future by her work, Hilla did not listen to her father.
Dr. Ben-Pazi is a senior neurologist with over two decades of experience in clinical studies and collaborative networks. She is also the founder and owner of the first tele-neurology company in Israel NeuroCan, and the winner of EIC WomenTech leadership program.
Dr. Hilla Ben-Pazi with a patient
A mother of four herself, Ben-Pazi has the experiences needed to work with children. And for her, this has been a two-way street. She was already working in the pediatric field when Dr. Ben-Pazi first started a family. As such, over the years she has been able to use her home life experiences to her work, and her work experiences to her home life.
As Hilla explained, “In some ways, it is easier to treat children because they do not yet have the life experiences that affect their views of what is happening to them.”
“They are optimistic,” she added, “kids laugh and play as soon as they feel well. And I love kids (don’t we all?!)
“One of the first observations from the clinical population was that the children with pathological movement almost always have behavioral, emotional, or psychiatric symptoms in addition to the movement disorder,” she said. “These emotional issues were in some cases more disabling than the movement disorder itself.”
So, why establish Avertto?
Dr. Ben-Pazi wants to make an impact, a difference in this world. “Isn’t this why we are all here?” she asks.
Hilla managed to combine all her life experiences and professional knowledge in developing Avertto. She brings it all to the table.
“As an entrepreneur, I have all it takes,” added Hilla. “My spouse’s and children’s support gives me the courage to dream and take risks. They believe that I can do it and won’t take any excuses as an answer.”
Avertto’s hybrid go-to-market strategy of in-patient clinical studies with a rigorous insertable domesticated regulatory pathway is the catalyst for large-scale adoption in the home market. The home market addresses 120 million patients annually who are at risk of stroke.
The company has raised $2 million in funding so far and Avertto has proof of concept. It is running blind clinical studies in 7 clinical sites around the world in countries like Israel, Spain, and the US.
Avertto boasts that it “tackles the global stroke crisis with its solution” which consists of a subcutaneous cloud-based, big data, tele-monitoring device using AI to detect changes in carotid pulse waves. In turn, timely alerts to healthcare providers are sent, enabling early stroke interventions. Avertto not only prolongs life but makes it worth living by intercepting strokes early and preventing disability outcomes.
Avertto, an Israeli medtech startup, offers the world’s first medical device with an AI- alert that warns a user of an impending stroke and enables early treatment. It is based on biological mimicry. This is yet another example of how the companies coming out of Israel Startup Nation are leading the world in medical, as well as high-tech, innovations.
Just think of this as another form of “light onto nations.”
One woman who can take personal credit for part of this is Dr. Hilla Ben-Pazi. In a world where young girls do not seek careers in medicine and science – mainly due to social and cultural constraints – she is a role model for all young girls and women who wish to be professionals while raising families.
This is someone who stands as a role model, a heroine, to all women.
An expert in pediatric movement disorders, in 2006, she opened Israel’s first clinic in this field at Shaare Zedek Medical Center in Jerusalem.
Dr. Ben-Pazi grew up in an Orthodox- Zionist family. From a very young age, she knew she wanted to be a doctor and do her share of “TIKUN OLAM” even though it was considered a challenging and untraditional career for a woman. Thankfully, for the many people she has helped to date and those who will be helped in the future by her work, Hilla did not adhere to norms.
Dr. Ben-Pazi is a senior neurologist with over two decades of experience in clinical studies and collaborative networks. She also founded the first teleNeurology company in Israel NeuroCan, two years before the Covid pandemic.
A mother of four herself, Ben-Pazi has the experiences needed to work with children. And for her, this has been a two-way street. She was already a mother when she started working in the pediatric field. As such, over the years, she has been able to use her home life experiences and her work experiences to her home life.
As Hilla explained, “In some ways, it is easier to treat children because they do not yet have the life experiences that affect their views of what is happening to them.”
“They are optimistic,” she added, “kids laugh and play as soon as they feel well. And I love kids (don’t we all?!)
“One of the first observations from the clinical population was that the children with pathological movement almost always have behavioral, emotional, or psychiatric symptoms in addition to the movement disorder,” she said. “These emotional issues were in some cases more disabling than the movement disorder itself.”
So, why establish Avertto?
Dr. Ben-Pazi wants to make an impact, a difference in this world. “Isn’t this why we are all here?” she asks.
Hilla manages to combine all of her life experiences and her professional knowledge in the development of Avertto. She brings it all to the table. She is the winner of the EIC WomenTech leadership program and won the prestigious Asper Prize at the Hebrew University.
“As an entrepreneur, I have all it takes,” added Hilla. “My spouse’s and children’s support gives me the courage to dream and take risks. They believe I can do it and won’t take any excuses as an answer.”
Founded in 2019, Avertto offers the first insertable medical device with an AI alert of impending strokes. Stroke is a $1 trillion problem around the world. It is the leading cause of disability. Stroke is treatable if detected in time; however, 85% of the cases remain untreated.
Avertto deals with this problem with its patented, subcutaneous telemonitoring medical device that uses AI and signal analysis to detect changes in the carotid pulse waves, sends “timely alerts” to prevent stroke before neurological damage occurs to healthcare providers, and initiates early neuroprotective treatment before reaching the hospital.
Avertto’s hybrid go-to-market strategy of in-patient clinical studies with a rigorous insertable domesticated regulatory pathway is the catalyst for large-scale adoption in the home market. The home market addresses 140 million patients annually who are at risk of stroke.
Avertto has proof of concept. It runs blind clinical studies in 4 sites in Israel and Spain. The company has raised $2 million in funding and is seeking $0.5M match funding for that last IIA grant.
Avertto boasts that it “tackles the global stroke crisis with its solution,” which consists of a subcutaneous cloud-based, big data telemonitoring device using AI to detect changes in carotid pulse waves and provides early treatment. In turn, timely alerts to healthcare providers are sent, enabling early medical stroke interventions. Avertto not only prolongs life but makes it worth living by intercepting strokes early and preventing disability outcomes.
And this is all thanks to Dr. Hilla Ben-Pazi. One of the women behind Israel Startup Nation.
